Extensive-stage Small-cell Lung Cancer Clinical Trial
Official title:
A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The main question it aims to answer is: • Does the administration of MGC018 achieve a clinically meaningful response rate of 25% in patients with relapsed or refractory ES-SCLC? Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will be done every 2 cycles (28 day cycles). Blood samples will be taken for biomarker analysis before treatment, on cycle 3 day 1, and at progression. A pretreatment biopsies will be done.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04985851 -
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
|
N/A | |
| Completed |
NCT01987232 -
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06427369 -
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06223711 -
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
|
Phase 2 | |
| Completed |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04790253 -
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
N/A | |
| Withdrawn |
NCT05572476 -
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05874401 -
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
|
Phase 4 | |
| Not yet recruiting |
NCT06008353 -
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
|
||
| Recruiting |
NCT04947774 -
Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
|
||
| Completed |
NCT04902885 -
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan
|
Phase 3 | |
| Active, not recruiting |
NCT05280470 -
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 2 | |
| Recruiting |
NCT05765825 -
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
|
Phase 2 | |
| Recruiting |
NCT05761977 -
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
|
||
| Active, not recruiting |
NCT05092412 -
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06306560 -
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
|
Phase 2 | |
| Recruiting |
NCT06211036 -
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
|
Phase 3 | |
| Recruiting |
NCT04894591 -
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
|
||
| Not yet recruiting |
NCT06437509 -
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06449209 -
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
|
Phase 2 |